Celyad Oncology SA (NASDAQ:CYAD – Get Rating) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 177,000 shares, a growth of 374.5% from the July 31st total of 37,300 shares. Based on an average trading volume of 136,100 shares, the days-to-cover ratio is currently 1.3 days.
Celyad Oncology Stock Performance
Shares of NASDAQ CYAD traded down $0.05 during mid-day trading on Thursday, reaching $1.95. 10,138 shares of the company traded hands, compared to its average volume of 66,226. Celyad Oncology has a fifty-two week low of $1.51 and a fifty-two week high of $5.32. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.71 and a quick ratio of 2.58. The stock has a fifty day simple moving average of $1.87 and a 200-day simple moving average of $2.13.
Get
Celyad Oncology alerts:
Celyad Oncology Company Profile
(Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
Further Reading
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- ShockWave Stuns With 40% Post-Earnings Price Move: Is It A Buy?
- NVIDIA: A Top Choice In Bifurcated Chip Market?
- PENN Entertainment Stock is Reset and Ready to Rebound
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Celyad Oncology SA(納斯達克：賽亞德-GET評級)是空頭股數8月份顯著增長的目標。截至8月15日，空頭股數共有177,000股，較7月31日的37,300股增長374.5%。以136,100股的平均成交量計算，目前天數與回補比率為1.3天。
Celyad腫瘤學股票表現
週四午盤，納斯達克賽德的股價下跌0.05美元，至1.95美元。該公司有10,138股易手，而其平均成交量為66,226股。Celyad Oncology的股價為52周低點1.51美元，52周高點為5.32美元。該公司的債務權益比為0.05，流動比率為1.71，速動比率為2.58。該股的50日簡單移動均線為1.87美元，200日簡單移動均線為2.13美元。
到達
塞利亞德腫瘤學警報：
Celyad腫瘤學公司簡介
(獲取評級)
Celyad Oncology SA是一家臨床階段的生物製藥公司，專注於發現和開發用於癌症治療的嵌合抗原受體T(CAR-T)細胞療法。它的主要候選產品包括用於治療轉移性結直腸癌的同種異體CAR-T候選藥物Cyad-101，處於1b期臨床試驗的轉移性結直腸癌；基於短髮夾狀RNA(ShRNA)的同種異體CAR-T候選藥物，正處於治療復發/難治性多發性骨髓瘤的第一階段臨床試驗；以及正在進行第一階段臨床試驗的自體CAR-T候選藥物Cyad-02，用於治療復發或難治性急性髓系白血病和骨髓增生異常綜合徵。
進一步閱讀
- 免費獲取StockNews.com關於Celyad腫瘤學的研究報告(CyAD)
- 威廉姆斯-索諾馬的高端消費者仍在消費
- 雪花股票因業績強勁而飆升
- 股價下跌40%的Shockwave Stunts：這是買入嗎？
- NVIDIA：分流晶片市場的首選？
- 賓夕法尼亞娛樂公司股票重置，準備反彈
接受Celyad腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Celyad Oncology和相關公司的最新新聞和分析師評級的每日簡要摘要。
